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Abstract
Purpose The thyroid-stimulating hormone receptor
(TSHR) is the target autoantigen for TSHR-stimulating
autoantibodies in Graves’ disease. The TSHR is composed
of: a leucine-rich repeat domain (LRD), a hinge region or
cleavage domain (CD) and a transmembrane domain
(TMD). The binding arrangements between the TSHR
LRD and the thyroid-stimulating autoantibody M22 or
TSH have become available from the crystal structure of
the TSHR LRD–M22 complex and a comparative model of
the TSHR LRD in complex with TSH, respectively.
However, the mechanism by which the TMD of the TSHR
and the other glycoprotein hormone receptors (GPHRs)
becomes activated is unknown.
Methods We have generated comparative models of the
structures of the inactive (TMD_In) and active (TMD_Ac)
conformations of the TSHR, follicle-stimulating hormone
receptor (FSHR) and luteinizing hormone receptor (LHR)
TMDs. The structures of TMD_Ac and TMD_In were
obtained using class A GPCR crystal structures for which
fully active and inactive conformations were available.
Results Most conserved motifs observed in GPCR TMDs
are also observed in the amino acid sequences of GPHR
TMDs. Furthermore, most GPCR TMD conserved helix
distortions are observed in our models of the structures of
GPHR TMDs. Analysis of these structures has allowed us
to propose a mechanism for activation of GPHR TMDs.
Conclusions Insight into the mechanism of activation of
the TSHR by both TSH and TSHR autoantibodies is likely
to be useful in the development of new treatments for
Graves’ disease.
Keywords Graves’ disease  Glycoprotein hormones 
Glycoprotein hormone receptors  TSHR structure 
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Introduction
The thyroid-stimulating hormone (TSH) receptor (TSHR)
is a class A G protein-coupled receptor (GPCR) and is the
target autoantigen in Graves’ disease [1, 2]. Patients with
Graves’ disease develop autoantibodies that bind the
extracellular domain (ECD) of the TSHR and activate the
receptor. The autoantibodies mimic the action of TSH
causing stimulation of thyroid hormone synthesis by thy-
roid cells, leading to hyperthyroidism in Graves’ disease
[1, 2].
GPCRs constitute a large superfamily of integral
membrane protein receptors. The first three-dimensional
structure of a complete GPCR (bovine rhodopsin) [3] was
solved in 2000. Since then a number of GPCR structures
have been solved by experimental methods, published and
deposited in the Protein Data Bank (PDB). All GPCR
structures share a core of seven membrane-spanning heli-
ces. The major differences between different GPCRs are
observed in the relative positions and contacts of the
helices with respect to each other and the length and
structures of their N termini, intracellular loops and
extracellular loops. As the number of available
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experimental GPCR structures increases, the homology or
comparative modelling methods can be used to obtain
reliable models of the structures of other GPCRs with
unsolved structures [4].
The TSHR belongs to the glycoprotein hormone recep-
tor (GPHR) subfamily, of the leucine-rich repeat-contain-
ing GPCR (LRG) family, of class A (or rhodopsin like)
GPCR [5]. The structure of the TSHR, as well as the other
GPHRs, is composed of a large amino-terminal extracel-
lular domain (ECD) and a transmembrane domain (TMD).
The TSHR ECD contains an N-terminal domain, a leucine-
rich repeat domain (LRD) and a hinge region or cleavage
domain. The TMD contains the typical seven transmem-
brane helices of GPCRs, an eighth helix parallel to the
membrane and a C-terminal tail. The crystal structures of
the LRD of the human (h) TSHR in complex with the
TSHR-stimulating human monoclonal autoantibody
(hMAb) M22 [6] and with the TSHR-blocking hMAb
K1–70 [7] are available. Also, the crystal structure of the
LRD and the ECD of the human FSH receptor (FSHR)
bound to hFSH has been determined [8, 9]. No experi-
mental structures of the TMD of the TSHR are available,
although several models of the structure of the TSHR TMD
have been published [10–18].
The availability of three GPCR crystal structures in their
fully active conformation, b2-adrenergic receptor, rho-
dopsin (metarhodopsin II) and M2 muscarinic acetyl-
choline receptor, has provided some insight into GPCR
activation [19–21]. Here, we present the comparative
models of the structures of the TMD of the TSHR in its
active and inactive conformations based on the same three
GPCR structures for which both, active and inactive crystal
structures are available, i.e. b2-adrenergic receptor, rho-
dopsin and M2 muscarinic acetylcholine receptor [19–24].
We also modelled structures of the TMDs of the FSHR and
LH receptor (LHR) in their active and inactive conforma-
tions. In addition, we produced a model of the structure of
the TSHR TMD in its inactive conformation based on 16
GPCR inactive structures. These structures have allowed us
to propose an activation mechanism for the TSHR TMD.
Methods
Three theoretical models of the structure of the TSHR
TMD have been obtained by comparative modelling using
the program MODELLER [25] within the Discovery Stu-
dio 3.5 suite of software (DS3.5) (http://accelrys.com/pro
ducts/discovery-studio/). The TSHR TMD structure
(TMD_I) was predicted using 16 homologous GPCR
experimental structures in their inactive state (Table 1).
The TSHR TMD structure (TMD_In) was predicted using
three homologous GPCR crystal structures (b2-adrenergic
receptor, metarhodopsin II and M2 muscarinic acetyl-
choline receptor) in their inactive state (Table 1). The
TSHR TMD structure (TMD_Ac) was predicted using the
same three homologous GPCR experimental structures as
for the structure of the TMD_In, but, in this case, in their
active state (Table 1). In addition, structures of the TMDs
of the FSHR and LHR in both active and inactive con-
formations were obtained using the same GPCR templates
used for the TSHR TMD structures. In the case of all
homologous GPCRs used, the coordinates of T4-lysozyme,
antibodies/nanobodies and G proteins/peptides were
removed. In addition, when the sequences of the segments
of the GPCRs and the TSHR TMD had different lengths,
the sequences of the homologous GPCRs were adjusted.
When the sequence of the TSHR TMD showed an insertion
compared to the sequences of the templates, one or two
residues of the templates were deleted at each side of the
insertion. When the sequence of the TSHR TMD showed a
deletion compared to the sequences of the templates, the
additional residues were deleted from the templates plus
one or two residues of the templates at each side of the
deletion. The deletion of one or two residues at the
boundaries of the insertions/deletions was dependent on the
structures of the templates. The crystal structure of the
extracellular loop 1 (ECL1) of the human smoothened
receptor (Table 1) was used to predict the structure of the
ECL1 of the three modelled structures of the TSHR TMD
(Table 1). The amino acid sequence identities between the
homologous GPCR and the TSHR TMD are shown in
Table 1. The same homologous GPCR structures used for
modelling the structure of the TSHR TMD were used for
modelling the active and inactive conformations of the
FSHR and LHR TMDs.
Three initial sequence alignments of the amino acid
sequences of the GPCR used as templates were obtained
using the program ClustalW [26]. The initial sequence
alignments were manually modified based on structural
alignments and superimpositions of coordinates of the
homologous GPCRs using DS3.5. Three initial alignments
of the amino acid sequence of the TSHR TMD (or the
FSHR and LHR TMDs) with the previous alignments of
GPCRs homologues were obtained using the program
ClustalW. The alignments were manually modified to
correct defects from the automatic alignment method of
ClustalW.
The structures of the TSHR TMD (or the FSHR and
LHR TMDs) predicted by MODELLER were validated
with the ‘Check Structure’ and ‘Profiles-3D’ functionalities
of DS3.5. The alignments were manually modified to
improve validation results, and the modelling and valida-
tion processes repeated until models with good geometry
and conformations were obtained. Finally, some short
sequence segments were remodelled by the ‘‘Loop
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Refinement’’ functionality within DS3.5 to correct struc-
tural defects.
Results
At the time of the study, the experimental structures of 18
different inactive GPCRs and three structures in the active
state were available from the PDB. The structures of 16
GPCRs in an inactive state were used as templates to build
an inactive structure of the TSHR TMD (TMD_I)
(Table 1). An active structure of the TSHR TMD
(TMD_Ac) was built based on the only three templates of
fully active GPCRs. Furthermore, an inactive TSHR
(TMD_In) structure was built based on the same three
templates used for TMD_Ac, but in their inactive states
(Table 1).
The TSHR TMD ECL1 is 14 residues long, whereas the
lengths of the ECL1 of the templates used for modelling
range from five to eight residues. Therefore, the ECL1
from the smoothened receptor, which is 26 residues long,
was used for modelling the structure of the ECL1 of the
TSHR TMD. The structure of the ECL1 of the smoothened
receptor shows a short a helix at its N terminus followed by
a b turn type II, then a segment bound to the top of the
TMD structure and finished by a b turn type I. The segment
bound to the top of the TMD structure has been used in the
modelling of the structure of the TSHR TMD ECL1
(Supplementary Fig. 1).
The ECL2 of the TSHR TMD is 23 residues long and
therefore challenging for predicting its structure in silico. A
sequence alignment of the ECL2 of the 16 GPCR tem-
plates, used for comparative modelling, with that of the
TSHR TMD (Supplementary Fig. 1) identified bovine
rhodopsin as having the highest amino acid sequence
identity (32%). The structure of the ECL2 of bovine rho-
dopsin shows a small two-stranded b sheet placed on the
top of the TMD structure, forming a ‘‘lid’’, followed by a
segment going up and finishing in a small a helix. The
structure of the TSHR TMD ECL2 may also act as a ‘‘lid’’,
because, as in the case of rhodopsin, no ligand is needed to
access the space between the transmembrane helices.
Accordingly, rhodopsin was selected as the most appro-
priate template for modelling the structure of the ECL2 of
the TSHR TMD.
The ICL3 shows great variation in length among the
GPCRs, from as short as five residues to a complete
domain present within the loop sequence in wild-type
proteins (Supplementary Fig. 1). The sequence of the
TSHR TMD ICL3 is one of the shortest, having five or





Used for the modelling of References
TMD_I TMD_In TMD_Ac
CXC chemokine receptor type 1 Human 2LNL Inactive NMR 20.7 4   [50]
b1-Adrenergic receptor Turkey 2VT4 Inactive 2.7 A˚ 18.4 4   [51]
Rhodopsin Squid 2Z73 Inactive 2.50 A˚ 17.6 4   [52]
Adenosine A2A receptor Human 3EML Inactive 2.60 A˚ 21.0 4   [53]
CXC chemokine receptor type 4 Human 3ODU Inactive 2.50 A˚ 19.5 4   [54]
Histamine H1 receptor Human 3RZE Inactive 3.10 A˚ 18.0 4   [55]
Sphingosine 1-phosphate receptor 1 Human 3V2Y Inactive 2.80 A˚ 17.5 4   [56]
Proteinase-activated receptor 1 Human 3VW7 Inactive 2.20 A˚ 17.6 4   [57]
M3 muscarinic acetylcholine receptor Rat 4DAJ Inactive 3.40 A˚ 20.5 4   [58]
j-Opioid receptor Human 4DJH Inactive 2.90 A˚ 18.0 4   [59]
l-Opioid receptor Mouse 4DKL Inactive 2.80 A˚ 18.8 4   [60]
Nociceptin/orphanin FQ receptor Human 4EA3 Inactive 3.01 A˚ 20.7 4   [61]
d-Opioid receptor Mouse 4EJ4 Inactive 3.40 A˚ 20.0 4   [62]
Rhodopsin Bovine 1U19 Inactive 2.20 A˚ 17.7 4 4  [22]
b2-Adrenergic receptor Human 2RH1 Inactive 2.40 A˚ 21.4 4 4  [23]
M2 muscarinic acetylcholine receptor Human 3UON Inactive 3.00 A˚ 19.7 4 4  [24]
Metarhodopsin II Bovine 3PQR Active 2.85 A˚ 17.7   4 [19]
b2-Adrenergic receptor-Gs protein
complex
Human 3SN6 Active 3.20 A˚ 21.4   4 [20]
M2 muscarinic acetylcholine receptor Human 4MQS Active 3.50 A˚ 17.7   4 [21]
Smoothened receptor Human 4LKV Inactive 2.45 A˚ – ECL-1 [63]
a Amino acid sequence identity between the TSHR TMD and the homologous GPCRs
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seven residues depending on possible variations in deter-
mining the beginning and the end of the loop. For the
purpose of modelling, the ICL3 segments of GPCR tem-
plates have been adjusted to match the length of TSHR
TMD ICL3, except for squid rhodopsin template. The
transmembrane helices (TMs) 5 and 6 flanking the ICL3 of
squid rhodopsin are longer than those of the other GPCRs.
The intracellular parts of TM5 and 6 and ICL3 of squid
rhodopsin were kept to obtain a better definition of the
structures of the TSHR TM5 and 6.
Comparative modelling of the structure
of the inactive TSHR TMD_I
The 16 structures of the inactive GPCRs with the highest
amino acid sequence identity (cutoff at 17.5%) compared
with the TSHR TMD sequence were used to model the
structure of TSHR TMD_I (Table 1). The amino acid
sequence alignment between the 16 homologous GPCRs
used for modelling and the TSHR TMD is shown in Sup-
plementary Fig. 1, together with the location and number
of residues that have been removed from the structures of
the homologous GPCRs, for the purpose of the study, and
the residues that are not visible in the experimental
structures.
The amino acid sequences of GPCRs show some highly
conserved motifs. One functionally important motif cor-
responds to the sequence E/D3.49RY3.51 in TM3 (super-
scripts refer to Ballesteros–Weinstein numbering [27],
Supplementary Fig. 2). The Arg residue of this motif forms
a salt bridge (ionic lock) with Glu6.30 of TM6 that stabilizes
the GPCR inactive state [28]. The TSHR shows the
sequence ERW (Glu5183.49, Arg5193.50, Trp5203.51) at the
equivalent position and an Asp6.30 at position 619 of TM6
(Supplementary Figs. 1 and 2), and in our model they form
the corresponding salt bridge of the ‘‘ionic lock’’. Fur-
thermore, a conserved direct or water-mediated hydrogen
bond network linking Asp2.50 of the NLxxxD motif in TM2
with Trp6.48 of the CWxP motif in TM6 is important for
maintaining the inactive conformation [29]. The sequence
of the TSHR shows the conserved motif 455-NLxxxD-460
in TM2 but not in TM6, where the corresponding sequence
is 636-CMxP-639 (Supplementary Fig. 1). A hydrogen
bond network is not observed in the structure of the
TMD_I; however, a water-mediated hydrogen bond net-
work cannot be ruled out as water molecules were not
included in the model.
Some GPCR structures have an a-bulge in the middle of
TM2. It was proposed that a-bulges are generated by
adjacent prolines; however, there are exceptions [30]. For
example, the muscarinic acetylcholine receptor M3
(mAChR M3, PDB-Id 4DAJ, Table 1) has the a-bulge in
its TM2 in the absence of an adjacent proline. The
sequence alignment between the TSHR TMD and its
homologous GPCRs (Supplementary Fig. 1) suggests the
presence of an a-bulge in the structure of TM2 of the
TSHR TMD, and even though no proline is present the a-
bulge was included in our model. A proline distortion is
observed close to the extracellular end of TM4 of most
GPCR structures. The presence of a proline at the same
position in the amino acid sequence of the TSHR TMD
TM4, Pro5564.60 (Supplementary Fig. 1), is a good indi-
cation that a similar distortion is likely to occur in the
structure of TM4 of the TSHR TMD and consequently the
model shows the distortion. Furthermore, out of the 18
available TMD structures, only the sphingosine 1-phos-
phate receptor 1 (S1P1, PDB-Id 3V2Y) does not present an
a-bulge in its TM5 or a proline, Pro5.50, in its TM5. The
sequence alignment between the TSHR TMD and its
homologous GPCRs (Supplementary Fig. 1) shows that no
proline is present in TM5 as in the case of the S1P1, and
therefore TM5 of the TSHR TMD does not present an a-
bulge (Fig. 1). A proline kink is observed in the structure
of the TSHR TMD TM6. A similar proline kink is observed
in the structures of all GPCR used as templates for mod-
elling (Fig. 1 and Supplementary Fig. 1). A similar situa-
tion is observed in TM7, where all GPCR templates and the
TSHR TMD show a proline kink (Fig. 1 and Supplemen-
tary Fig. 1).
For the modelling of the structure of the TSHR TMD_I
ECL2, we have used the ECL2 structure of rhodopsin and
ECL2 structures similar to that of rhodopsin found in five
GPCRs. (Supplementary Fig. 1). The conserved disul-
phide bond between the cysteines of the ECL2 and TM3 is
present in the structure of the TSHR TMD_I. The ICL2 of
the TSHR TMD_I shows a small a helix similar to that
observed in some of the structures of GPCRs used as
templates for modelling (Fig. 1 and Supplementary
Fig. 1). For ICL3, the whole structure of squid rhodopsin
ICL3 was used for modelling. The structures of the
cytoplasmic ends of TM5 and TM6 of squid rhodopsin are
about two-and-a-half helix turns longer for each helix
compared to the other GPCRs used as templates. Using
squid ICL3 for modelling helped in defining good helical
structures of the cytoplasmic ends the TSHR TM5 and
TM6 helices.
Comparative modelling of the structure
of the inactive TSHR TMD_In (three homologues)
A comparative model of the structure of the inactive TSHR
TMD (TMD_In) has been obtained based on the structures
in an inactive conformation of the same three GPCRs for
which their active conformation structures are available
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(b2-adrenoceptor, metarhodopsin II and M2 muscarinic
acetylcholine receptor) (Table 1). The amino acid sequence
alignment between the three homologous GPCRs used for
modelling and the TSHR TMD is shown in Supplementary
Fig. 3, together with the location and number of residues
that have been removed from the structures of the homol-
ogous GPCRs and the residues that are not visible in the
experimental structures.
In the model of the structure of TSHR TMD_In (Fig. 1),
the Arg residue of the conserved motif 518-E/D3.49RY3.51
(Glu/Asp518, Arg519, Tyr520) is involved in an electro-
static interaction with Asp6196.30 of TM6, forming an
‘‘ionic lock’’ that stabilizes the inactive conformation
(Fig. 1). In contrast, Tyr6787.53 from the conserved motif
N7.49PxxY7.53 in TM7 is *11 A˚ away from Tyr6015.58 in
TM5 and this distance makes formation of a water-medi-
ated hydrogen bond impossible, consistent with an inactive
conformation. Furthermore and similarly to the structure of
the TMD_I, the hydrogen bond network connecting
Asp4602.50 of the 455-NLxxxD-460 motif in TM2 with
Met6376.48 of the 636-CMxP-639 motif in TM6 is not
observed in the modelled structure of the TMD_In. As the
model does not include water molecules, a water-mediated
hydrogen bond network cannot, however, be ruled out.
Similar to the structure of the TSHR TMD_I, the
structure of the TMD_In shows an a-bulge in the middle of
TM2 but not in TM5 (Fig. 1). In addition, similar proline
distortion to that observed close to the extracellular end of
TM4 of the TMD_I is observed in the structure of the
TMD_In (Fig. 1). Proline kinks are also observed in the
structures of TM6 and TM7 of the TSHR_In (Fig. 1) as in
the case of the TMD_I. In addition, the conserved disul-
phide bond between cysteines of the ECL2 and TM3 is also
observed. The ICL1 of the TSHR TMD_In shows a small a
helix similar to that observed in two of the three structures
of GPCRs used as templates for modelling (Fig. 1 and
Supplementary Fig. 1). In contrast to the TMD_I structure,
no small a helix is observed in the structure of the ICL2 of
the TMD_In.
Comparative modelling of the structure of the active
TSHR TMD_Ac (three homologues)
The structure of the TSHR TMD in its active conformation
(TMD_Ac) has been obtained by comparative modelling
based on the structures of the only three GPCRs for which
fully active conformation structures are available (b2-
adrenoceptor, metarhodopsin II, and M2 muscarinic
acetylcholine receptor) (Table 1). The same three GPCRs
in the inactive conformations were used for modelling the
structure of the inactive TSHR TMD (TMD_In). This
allowed a comparison of the active and inactive confor-
mations of the TSHR TMD. The amino acid sequence
alignment between the three homologous GPCRs used for
modelling and the TSHR TMD is shown in Supplementary
Fig. 4, together with the location and number of residues
that have been removed from the structures of the homol-
ogous GPCRs and the residues that are not visible in the
experimental structures.
In the model of the structure of the TMD_Ac (Fig. 1),
the Arg5193.50 residue of the conserved motif E/DRY is
*13 A˚ away from Asp6196.30 of TM6 breaking the ‘‘ionic
lock’’ as expected for an active conformation (Fig. 1).
Another functionally important GPCR motif, N7.49PxxY7.53
in TM7, makes a water-mediated hydrogen bond with the
highly conserved Tyr5.58 in TM5 in the structures of acti-
vated b2-adrenoceptor and metarhodopsin II. The water-
mediated hydrogen bond, only possible in the active state,
may contribute to active state stability in GPCRs, serving
as an active state counterpart to the ‘ionic lock’ that sta-
bilizes the inactive state [31]. The TSHR shows the exact
amino acid sequence, 674-NPxxY-678, of this highly
conserved motif and also shows a tyrosine in TM5 at
position 5.58 (Tyr601) (Supplementary Figs. 1 and 2).
TSHR TMD_Ac Tyr6787.53 from the NPxxY motif is at a
non-interacting distance of *4.6A˚ from Tyr6015.58 in
TM5. This distance is similar to that observed in the
structure of metarhodopsin II (*5.0 A˚) which has the two
tyrosines hydrogen bonded through a water molecule sta-
bilizing the active conformation. Although the model of the
structure of TMD_Ac does not show positions of water
molecules, it is expected that the TMD_Ac equivalent
tyrosines would be involved in a water-mediated hydrogen
bond.
In a similar way to the structures of TSHR TMD_I and
TMD_In, the structure of TMD_Ac shows an a-bulge in
the middle of TM2 (Fig. 1), but not in the structure of
TM5. In addition, similar proline distortion to that seen
bFig. 1 Comparative models of the structure of the transmembrane
domain (TMD) of the thyroid-stimulating hormone receptor (TSHR)
in three different orientations related by 90 rotations along a vertical
axis. TMD_I is based on 16 G protein-coupled receptor (GPCR)
structures in their inactive conformations. TMD_In is based on three
GPCR structures in their inactive conformations. TMD_Ac is based
on the same three GPCRs as TMD_In, but in their active conforma-
tions. Transmembrane helices (TM), extracellular loops (ECL),
intracellular loops (ICL), C-terminal tail (C-tail) and N- and
C-termini (N, C) are marked. Sequence motifs (blue background
circles) and structural features (yellow background circles) of the
transmembrane domain of the TSH receptor in their active and
inactive conformations are shown. Ionic lock (1), N674PxxY678 motif
(2) in TM7, N455LxxxD460 motif (3) in TM2 and C636MxP639 motif
(4) in TM6. Alpha bulge (5) in TM2, proline distortion (6) in TM4,
proline kink (7) in TM6 and proline kink (8) in TM7. The G-protein
binding site is clearly visible at the cytoplasmic end of the active
conformation. Reproduced with permission from copyright holder
RSR Ltd
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close to the extracellular end of TM4 of the TMD_I and
TMD_In is observed in the structure of the TMD_Ac
(Fig. 1). Finally, proline kinks are also observed in the
structures of TM6 and TM7 of the TSHR_Ac (Fig. 1) as in
the case of the TMD_I and TMD_In. In addition, the
conserved disulphide bond between cysteines of the ECL2
and TM3 is also observed. The ICL1 and ICL2 of the
TSHR TMD_Ac show small a helices similar to those
observed in some of the structures of GPCRs used as
templates for modelling (Fig. 1 and Supplementary Fig. 1).
Comparative modelling of the structures
of the TMDs of the FSHR and LHR
The structures of the active and inactive conformation of
the FSHR TMD and LHR TMD were obtained by com-
parative modelling based on the same GPCR structures, in
their inactive and fully active conformations, used for
modelling the TSHR TMD_In and TMD_Ac. The struc-
tures of the inactive and active conformations of the TMDs
of the FSHR and LHR are highly similar to the structures
of the inactive and active conformations of the TSHR
TMD, respectively.
All major GPCR-conserved motifs show the same
sequences in the three GPHRs, i.e. NLxxD2.50, ERW3.51,
CMxP6.50 and NPxxY7.53. In addition, similar to the
structures of the TSHR TMD, an a bulge is observed in
the structures of TM2, but not TM5 of the FSHR and
LHR TMDs. Similar proline distortion in TM4 and
proline kinks in TM6 and TM7 are observed in the
structures of the three GPHRs. Functionally important
interactions are similar in the three GPHRs. For exam-
ple, the ionic lock observed in most GPCRs, a salt bridge
between Arg3.50 in TM3 and Asp/Glu6.30 in TM6, is
observed in the inactive conformations of the three
GPHRs (Arg467 and Asp567 in the FSHR, Arg464 and
Asp564 in the LHR, and Arg519 and Asp619 in the
TSHR), but it is broken in the three active conforma-
tions. Similarly, the possible water-mediated hydrogen
bond between Tyr5.58 in TM5 and Tyr7.53 in TM7,
observed in the active conformation of the TSHR TMD,
is also possible in the active conformations of the FSHR




It has been proposed that comparative modelling using
multiple templates would produce more accurate models
compared to the models based on a single template [32, 33]
provided that the templates have similar levels of sequence
identity with the target sequence. In particular, a model
based on a single template would be highly similar to the
chosen template and may not be the best representation of
the target structure. In contrast, multi-template modelling
would produce a model with an average structure of the
templates and after minimization would be expected to be a
better representation of the target structure. In this study,
we have produced a model of the structure of the inactive
TSHR (TSHR TMD_I) based on 16 of the 18 GPCRs
templates in their inactive states available at the time of the
study. Consequently, the TSHR TMD_I model is likely to
represent an accurate structure of the inactive TSHR TMD.
However to compare the models of the inactive and active
conformations of the TSHR (as well as FSHR and LHR),
the models should be produced based on templates of the
inactive and active conformations of the same GPCRs.
Therefore, we have built comparative models of the inac-
tive and active conformations of the three receptors based
on the three GPCRs for which structures of both inactive
and fully active conformations were available at the time of
the study. The structures of partially active conformations
were not considered as suitable templates as they present
features of active conformations in the extracellular parts
of the receptors and features of inactive conformations in
the cytoplasmic parts. To date, a comparison of the inactive
and active conformations of the GPHRs to infer an acti-
vation mechanism of the TMD has not been carried out.
The majority of previously published models of the active
state of GPHRs were based only on one template
[11–13, 15–18]. In one study, a model of the TSHR TMD
was produced based on 15 GPCRs in their inactive con-
formations, 3 GPCRs in partially active conformations and
1 in fully active conformation [14]. However, a receptor
model obtained in this way would not show either inactive
or active conformation. In addition, Schaarschmidt et al.
[10] have obtained an active conformation of the TSHR
TMD based on five partially active and two fully active
GPCR template structures. A model of the active TSHR
TMD, obtained in this way, is likely to represent the
inactive conformation in its cytoplasmic region rather than
the active conformation. In contrast, in our study we
analysed the activation of the GPHR TMDs based on the
TMD_In and TMD_Ac structures of the three receptors.
TSHR TMD structure
The structures of the TSHR TMD (and the FSHR and LHR
TMDs) are similar to those of typical GPCRs, with seven
transmembrane helices, an eighth helix parallel to the
membrane, three extracellular loops, three cytoplasmic
loops and a C-terminal tail. The interactions between
GPCR residues of conserved motifs are also observed in
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the structures of the TSHR TMD (and the FSHR and LHR
TMDs) including a functionally important ‘ionic lock’ in
the inactive state that is not present in the active state.
The structures of our three models of the TSHR TMD
and the models of the FSHR and LHR TMDs show an a-
bulge in the middle of TM2 (Fig. 1), but not in the structure
of TM5, as previously predicted by Chantreau et al. [11].
GPHRs have an alanine at position 5.50 (Ballesteros–We-
instein numbering [27]) of TM5 in contrast to other GPCRs
that have a conserved Pro in this position and consequently
a kink in the structure of TM5. Therefore, the models of the
structures of TM5 of GPHRs show a regular a helix
without a kink, as predicted previously by Kleinau et al.
[15] and Chantreau et al. [11]. TSHR mutation A5935.50P is
likely to induce a kink in the TM5 structure that would
probably affect folding of the mutated receptor. Indeed, the
cell surface expression of TSHR A593P has been deter-
mined to be *6% of TSHR wild type [15].
Strong hydrophobic interactions are observed in the
GPHR subfamily between residues at positions 3.30
(Phe447 in FSHR, Phe444 in LHR and F499 in TSHR) and
4.58 (Leu502 in FSHR, Met499 in LHR and Leu554 in
TSHR). These interactions are observed for both active and
inactive conformations of GPHRs. However, equivalent
interactions are not observed in the three GPCR crystal-
lized in their active conformation, whereas four of the 18
GPCR inactive experimental structures used in this study
(16 structures used as templates plus 2 structures not used
as templates due to low amino acid sequence identity)
show weak contacts between residues at positions 3.30 and
4.58. In contrast, the remaining 14 GPCR structures do not
show this interaction. Consequently, as experimental
structures of other members of the leucine-rich repeat-
containing GPCR family are not available as yet, the
hydrophobic interactions between residues at positions
3.30 and 4.58 observed in our models may be considered
specific for the GPHR subfamily.
TSHR TMD activation
The crystal structure of the FSHR ECD without the
TMD, solved by Jiang et al. [9], shows the ECD in its
active conformation. This indicates that the ECD can
adopt the active conformation in the absence of the
TMD. In addition, in most class A GPCRs the ECDs are
not involved in activation, suggesting that the TMD is
likely to activate independently of the ECD. According
to this, the activation mechanism of GPHRs can be
defined by the following independent steps: binding of
the hormone or an agonist stimulating antibody to the
LRD of the receptor’s ECD; activation of the ECD of the
receptor; signal transduction from the ECD to the TMD;
activation of the TMD; and activation of the G protein.
In this study, we have analysed the step involving acti-
vation of the TMD of the receptors.
The available GPCR crystal structures mainly define
three different conformations: an ‘‘inactive state’’ in which
the receptor is bound to an antagonist or inverse agonist; an
‘‘agonist-bound state’’ but without the G protein, or a
G-protein equivalent; and a ‘‘fully active state’’ in which
the receptor binds to an agonist and to a G protein or a
G-protein equivalent, forming a ternary complex. Inter-
mediate conformations are observed between these three
states. Agonist-unbound GPCRs usually show basal activ-
ity that is enhanced by agonist binding, reduced by inverse
agonist binding, unaffected by neutral antagonists and
increased by mutations that lead to constitutively active
mutants (CAMs). CAMs displace the active–inactive
equilibrium of GPCRs to the active state side [37]. Until
2002, constitutive activities had been observed in more
than 60 wild-type GPCRs [34]. More recently, Martin et al.
[35] have reported constitutive activity in 75% of the 40
orphan class A GPCR they studied. In the case of GPHRs,
although the wild-type TSHR shows high levels of con-
stitutive activity, the wild-type FSHR and LHR display
little constitutive activity if any [36].
Mechanisms of activation of class A GPCRs have been
unified by Tehan et al. [37]. Activation of GPCRs mostly
results in a slight rotation and upward movement of TM3, a
rotation of TM6 and inward movements of TM1, TM5 and
TM7. The disruption of the ionic lock, between TM3 and
TM6, may facilitate the movements of TM3 and TM6
during activation. However, more important is the
hydrophobic rearrangement of residues Leu3.43, Phe6.44,
Xxx6.40 (Xxx being one of the bulky hydrophobic amino
acid, Ile, Leu, Val or Met) and the less important Xxx6.41,
between TM3 and TM6 in the core of the receptor [37].
Figure 1 shows the structures of the three models of the
TSHR TMD. The structure of the active conformation,
TMD_Ac, shows a clear difference when compared with
the inactive conformation, TMD_In. The G-protein binding
site is evident in the structure of the TMD_Ac.
To show the conformational movements during the
activation process of the TSHR TMD, a superimposition of
the structures of TMD_In and TMD_Ac has been produced
(Fig. 2). The movements during activation of the trans-
membrane helices at their extracellular ends involve
(Fig. 2a) inward movements of TM1and TM7 towards the
core of the helix bundle, upward movements of TM3 and
TM6 and a small lateral movement of TM6. The move-
ments of the intracellular ends of the transmembrane
helices (Fig. 2b) involve outward movements of TM1 and
TM6 away from the core of the helix bundle, inward
movements of TM5 and TM7, a downward movement of
TM3 and a rotation of TM6 (Fig. 2c). These movements
are similar to those observed in other GPCRs [37].
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Similar to other GPCRs, in the structure of the TSHR
TMD, the ionic lock between Arg5193.50 in TM3 and
Asp6196.30 in TM6 is present in the inactive state and
absent in the active state. In the active state, Arg5193.50 is
hydrogen bonded to Tyr6015.58 in TM5, whereas
Asp6196.30 is hydrogen bonded to the backbone carbonyl
oxygen of Val6085.65 in TM5. Furthermore, in the inactive
TSHR TMD structure, Asn6747.49 in TM7, is hydrogen
bonded to Asp4602.50 in TM2, and the latter is also
hydrogen bonded to Ser6717.46 in TM7. In the TSHR TMD
active state, Asn6747.49 remains hydrogen bonded to
Asp4602.50 with the latter also hydrogen bonded to
Ser6717.46, but both hydrogen bonds are stronger than in
the inactive conformation. In addition, in the active state,
Asn6747.49 and Asp4602.50 are both hydrogen bonded to
Ser5083.39, in TM3. A proposed direct interaction between
Asp6336.44 and Asn6747.49, based on mutations experi-
ments [38], is not observed in the structure of the model of
the inactive TSHR TMD; however, a water-mediated
hydrogen bond is possible (distance of 4.6 A˚). In the
structure of the inactive TSHR TMD model, Asp633 is
hydrogen bonded to the neighbouring Asn6707.45 not
Asp6747.49 (Supplementary Table 3).
Activation of the TSHR TMD involves rearrangements
of hydrophobic residues. In the inactive state, TSHR
Leu5123.43 in TM3 makes hydrophobic contacts with both
Leu6296.40 and Ile6306.41 in TM6, whereas in the active
state it makes only one hydrophobic contact with
Leu4562.46 in TM2. Instead of Pro5.50 in TM5 that is highly
conserved in most GPCRs, the GPHRs have an alanine
(Ala5935.50). TSHR TMD activation involves the breaking
of the hydrophobic interaction between Ala5935.50 (in
TM5) and Val5093.40 (in TM3) and the formation of a new
hydrophobic interaction between Ala5935.50 and Thr5133.44
(in TM3). In addition, GPHRs have a charged Asp amino
acid (Asp6336.44) in TM6 instead of the highly conserved
hydrophobic Phe6.44 observed in most GPCRs. In the
inactive state, TSHR Asp6336.44 makes a hydrogen bond
with Asn6707.40 (in TM7), a possible water-mediated
hydrogen bond with Asn6747.44 (in TM7) [39] and an
induced dipole and hydrophobic interactions with
Leu5123.43, from TM3. In the TSHR TMD active state,
Asp6336.44 also makes an induced dipole interaction with
Leu5123.43 (in TM3) and a polar interaction with the
backbone carbonyl oxygen of Leu6296.40 (in TM6). Thus,
activation of the TSHR TMD involves breaking of the
interactions of Asp6336.44 in TM6 with Asn6707.40 and
Asn6747.44 in TM7. Our models of active and inactive
conformations of the three GPHR TMDs show that acti-
vation of the FSHR TMD and LHR TMD is likely to
involve similar interaction rearrangement to those observed
for the TSHR TMD.
Activating mutations in the TMD of GPHRs
The GPHR family contains the functionally important
Leu3.43 and Asp6.44 that stabilize the inactive state of the
receptor, while GPCRs have Phe6.44 instead of Asp6.44 [37].
Three naturally occurring TSHR Leu3.43 polar mutants (Q/
N/R) that increase receptor constitutive activity [40–42]
Fig. 2 Movements of the




the activation process. Orange
arrows indicate direction of
movement. a View from the
extracellular side. b View from
the intracellular side. c Rotation
of TM6 shown by the position
of Lys618 in the inactive and
active states. Lys618 in the
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show reduced inter-helical packaging. In addition, four
natural TSHR Asp6.44 mutants (A/E/H/Y), also associated
with increased receptor constitutive activity [43–45], break
or modify the interaction between Asp6.44 and Asn7.49.
Mutational studies have shown that the interaction between
Asp6.44 and Asn7.49 stabilize the inactive state of the TSHR
TMD [38]. In the case of the LHR, one naturally occurring
Leu3.43 mutant [46] and three Asp6.44 mutants [47–49] that
increase the constitutive activity of the receptor have been
reported. In contrast, no naturally occurring activating
mutants are reported at present for hFSHR at Asp6.44. Our
models are consistent with the observations from naturally
occurring activating mutations as described above (TSHR
TMD activation).
Tables 2, 3 and 4 show a list of GPHR CAMs taken
from the literature, whereas Supplementary Tables 1–3 list
the main interactions involving the mutated residues of the
CAMs as observed in the comparative models of the
structures of the GPHRs. For example, the model of the
structure of the FSHR shows that Met4012.43 makes a
hydrophobic interaction with Ile4633.46 in the inactive
conformation and an induced dipole interaction with
Arg4673.50 in the active conformation (Supplementary
Table 1). Substitution of Met401 for a Thr in the FSHR
increases the constitutive activity of the mutant 3.6-fold
compared to wild type (Table 2). The new Thr at position
2.43 of the mutated receptor may lose the hydrophobic
interaction with Ile463 in the inactive conformation or
change it to an induced dipole interaction. In addition, the
induced dipole interaction of Met401 with Arg467 in the
active conformation is likely to result in hydrogen bond
formation between Thr401 and Arg467 in the mutated
receptor. Both modifications are likely to stabilize the
active state which is in agreement with an increase in
constitutive activity. In contrast, Met3982.43 in the model
of the structure of the LHR makes two strong and one weak
hydrophobic interactions in the inactive conformation and
two weak hydrophobic interactions in the active confor-
mation (Supplementary Table 2). Breaking of these inter-
actions by the M398T mutation would destabilize the
inactive conformation more than the active conformation
and this is consistent with a 25-fold increase in constitutive
activity compared to the wild-type receptor (Table 3).
In another example, L3.43R mutation increases consti-
tutive activity for the TSHR, FSHR and LHR (3.2, 5 and 10
times wild-type receptor activity, respectively, Tables 2, 3,
4). In the models, Leu3.43 undergoes similar interactions in
the three receptors: short distance induced dipole with
Asp6.44 in both the active and inactive conformations; long
distance hydrophobic interaction with Leu2.46 in both
conformations; short distance hydrophobic interaction with
Tyr7.53 in the active conformations; and long distance
induced dipole interactions with Asn7.45 and Asn7.49 in the
active conformations (Supplementary Tables 1–3). In the
L3.43R mutants of the GHPRs, the interactions in the active
conformations between the new Arg3.43 and Asn7.45 and
Asn7.49 are likely to be hydrogen bonds. This situation
would stabilize the active conformation, increasing the
constitutive activity of the three receptors as observed
experimentally (Tables 2, 3, 4).
TSHR mutation L6657.40F increases receptor constitu-
tive activity threefold compared to wild type (Table 4) in
COS-7 cells transfected with the wild-type and mutated
TSHR. Cell surface expression of the L6657.40F mutant is
97% of that of the wild-type TSHR. Stimulation of the
mutant by 100 mU/mL TSH produced a slightly higher
cAMP accumulation (65.2 nM) than that of the wild-type
TSHR (52.7 nM) [14]. As indicated in Supplementary
Table 3, the TSHR residue Leu665 is not involved in
interactions with the other helices or loops in any of the
models of the two conformations of the TSHR TMD, active
and inactive. In the inactive conformation, the side chain of
Leu6657.40 is 5.4, 5.7 and 5.8 A˚ away from the side chains
of Leu4682.58, Val4211.39 and Val4241.42, respectively
(Fig. 3a). In the active conformations, Leu6657.40 is loca-
ted at shorter but still non-interacting distances, 4.4, 5.2
and 4.8 A˚ away from the side chains of Leu4682.58,
Val4211.39 and Val4241.42, respectively (Fig. 3a). Intro-
duction of a longer side chain at position 665 by the L665F
mutation is likely to generate hydrophobic interactions
with the side chains of some of the above-mentioned
residues. In particular, the mutated TSHR Phe665 is likely
to interact with Val424 at *3.9 A˚ in the inactive confor-
mation (Fig. 3b) and to form a double hydrophobic inter-
action at *3.0 and *3.4 A˚ in the active conformation
(Fig. 3b). This implies that the mutant stabilizes the active
more than the inactive conformation, consistent with a
Table 2 FSH receptor-activating mutations reported in the literature
Mutation BW number Type Activity References
M401T 2.43 CAM cAMP 3.60-fold WT [64]
T449A 3.32 CAM cAMP 2.5-fold WT [65]
L460R 3.43 CAM cAMP 5-fold WT [66]
I545T 5.46 CAM cAMP 2.3-fold WT [65]
I545L 5.46 CAM cAMP 4.53-fold WT [64]
D567N 6.30 CAM cAMP 3-fold WT [65]
M574I 6.37 CAM cAMP 2.19-fold WT [64]
A575V 6.38 CAM cAMP 2.95-fold WT [64]
I578L 6.41 CAM cAMP 2.49-fold WT [64]
T580I 6.43 CAM cAMP 5.41-fold WT [64]
Mutations causing increase of constitutive activity less than twofold
of WT are not included
CAM constitutively active mutant, BW Ballesteros–Weinstein num-
bering, WT wild type
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higher constitutive activity of the mutant with respect to
the wild-type receptor. Jaeschke et al. [14] also studied the
L6657.40F mutant with their model of the TSHR TMD
based on the templates of inactive, partially active and fully
active GPCRs. Their model predicted an interaction
between Leu665 and Val421 and suggested a steric
repulsion of the longer side chain of Phe655. This obser-
vation contrasts with the interpretation from our models
that suggests additional interactions that occur in the active
conformation of L655F mutant formed by the long side
chain of Phe655. Jaeschke et al.’s [14] prediction was
supported by comparing the structures of inactive and
partially active A2A adenosine receptor, showing an
increased distance between the residues equivalent to
Leu665 and Val421 in the partially active conformation. In
contrast, when comparing inactive with fully active con-
formations, the situation reverses. The distance between
the residues equivalent to Leu665 and Val421 in the
inactive rhodopsin (PB-Id: 1U19) is 3.8 A˚ between the side
chains and 9.0 A˚ between the alpha carbon atoms (Ca),
whereas in the fully active conformation (PDB-Id: 3PQR)
those distances are 3.2 and 8.8 A˚, respectively. In the case
of the b2-adrenoceptor (inactive: 2RH1, fully active:
3SN6), the distances in the inactive state are 3.9 A˚ between
side chains and 10.0 A˚ between Cas, whereas in the fully
active state the distances are 3.9 and 9.3 A˚, respectively.
For the inactive M2 muscarinic receptor (3UON), the dis-
tances are 4.1 and 9.6 A˚, whereas for the fully active
receptor (4MQS) they are 3.5 and 8.5 A˚, respectively.
These observations suggest that helices TM1 and TM7 as
well as Leu655 and Val421 approach each other during
activation. Furthermore, the effects of substitutions with
small amino acids in mutations V421A or L665V resulting
in TSHR variants exhibiting ligand-induced cAMP levels
similar to or below the levels of the wild-type receptor
were inconsistent with steric repulsion proposed by
Jaeschke et al. [14] in their model. In contrast, in our
models the proposed additional interactions produced by
V421 and L665 in the active state of the receptor would be
weakened by substitutions with the residues with smaller
side chains.
Silencing and inactivating mutations in the GPHR
TMDs
Tables 5, 6 and 7 show a list of silencing and/or inacti-
vating mutations taken from the literature, whereas Sup-
plementary Tables 4–6 list the main interactions in which
those mutant residues are involved. For example, FSH-
induced cyclic AMP production is abolished by the FSHR
mutation A5756.38V (Supplementary Table 4). In both
models of the active and inactive conformations of the
FSHR TMD, Tyr5535.62 is exposed to the membrane. In the
active conformation, the hydroxyl group of Tyr553 is
located in the area that contacts the polar heads of lipids at
the inner side of the membrane, making favourable inter-
actions. In the inactive conformation, the hydroxyl group
of Tyr553 is located in an area that contacts the aliphatic
Table 3 LH receptor-activating
mutations reported in the
literature
Mutation BW number Type Activity References
A373V 1.46 CAM cAMP 7.5-fold WT [67]
M398T 2.43 CAM cAMP 25-fold WT [68]
L457R 3.43 CAM cAMP 10-fold WT [46]
I542L 5.55 CAM cAMP 7-fold WT [48]
D564G 6.30 CAM cAMP 5-fold WT [48]
A568V 6.34 CAM cAMP 4-fold WT [69]
M571I 6.37 Activating – [70]
A572V 6.38 Activating – [70]
I575L 6.41 CAM cAMP 20-fold WT [71]
T577I 6.43 Activating – [70]
D578G 6.44 CAM cAMP 6.6-fold WT [49]
D578Y 6.44 CAM cAMP 13-fold WT [48]
D578E 6.44 CAM cAMP 4.3-fold WT [49]
D578H 6.44 CAM cAMP 14.4-fold WT [72]
D578Q 6.44 CAM cAMP 10.2-fold WT [72]
C581R 6.47 CAM cAMP 5-fold WT [48]
N615R 7.45 CAM cAMP 2.6-fold WT [72]
Mutations causing increase of constitutive activity less than twofold of WT are not included
CAM constitutively active mutant, BW Ballesteros–Weinstein numbering, WT wild type
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tails of the lipids in the membrane which introduces
instability by placing the polar tyrosine hydroxyl group in a
hydrophobic environment. In the FSHR TMD A575V
mutant, the side chain of Val575 covers the hydroxyl group
of Tyr553, in the inactive conformation, and protects it
from contacting the membrane, which increases the sta-
bility of the inactive conformation of the TMD. In the
active conformation, Tyr553 is not affected by the A575V
mutation. The increased stability of the inactive confor-
mation is consistent with the experimentally demonstrated
reduced activation of the mutated receptor.
In another example, LH-induced cyclic AMP production
by LHR is abolished by the LHR A5936.59P mutation
(Table 6). In the model of the inactive conformation of the
LHR TMD wild type, the beta carbon atom of Ala5936.59
forms a hydrophobic interaction at 3.4 A˚ with the delta 1
carbon atom of Ile5285.40 (Supplementary Table 5). No
interaction is observed in the model of the active confor-
mation, as the distance between these two residues is
4.9 A˚. In the inactive conformation of the LHR TMD
A5936.59P mutant, Pro5936.59 is likely to have additional
hydrophobic interaction with Ile5285.40. In particular, the
gamma carbon atom of Pro593 is likely to interact with the
delta 1 carbon atom of Ile528 at 3.4 A˚, and the beta carbon
atom of Pro593 is likely to interact with the delta 1 and the
gamma 1 carbon atoms of Ile528 at 3.4 and 4.0 A˚,
respectively. The extra interactions between Pro593 in
TM6 and Ile528 in TM5 in the inactive conformation may
block the rotation and displacement of TM6 needed for
LHR activation, making the A593P mutant unable to be
activated by LH, as observed experimentally (Table 6).
TSHR F594I and F634I single mutants have been
reported to cause silencing of the constitutive activity of
the receptor to *13% of the wild type (Table 7). The
model of the inactive conformation of the TSHR TMD
predicts an aromatic interaction between Phe5945.51 and
Phe6346.54 at 2.9 A˚ (Supplementary Table 6, Fig. 3d).
Substitution of any phenylalanine with isoleucine is likely
to maintain a hydrophobic interaction due to this short
distance. In addition, the model of the active conformation
of the TSHR TMD predicts an aromatic interaction
between the two phenylalanines at 3.6 A˚ (Supplementary
Table 6, Fig. 3d). Substitution of any phenylalanine with a
residue with a shorter side chain, for example isoleucine, is
likely to eliminate the interaction. In the active wild type
receptor, the distance between the interacting phenylala-
nines is longer than in the inactive wild-type receptor.
Consequently, substitution of any of these two phenylala-
nines with isoleucine is likely to have little effect on the
inactive conformation of the receptor, while destabilizing
the active conformation, consistent with the reduction of
constitutive activity observed for both receptor mutants.
In a final example, the model of the inactive confor-
mation of the TSHR TMD predicts that Asn6747.49
makes a polar interaction or weak hydrogen bond, with
Asp6336.44 (at 3.8 A˚) (Supplementary Table 3, Fig. 3c).
TSHR mutant D633A increases the constitutive activity
by 13.6-fold compared to the wild type (Table 4), even
though the cell surface expression of the mutant is only
26% of that of the wild-type TSHR. The TSHR D633A
mutant also shows an increase in maximum cAMP
accumulation of 50% compared to wild type when
stimulated by 10 mIU/ml bTSH. This increase in con-
stitutive activity of the mutant is due to a destabilization
of the inactive conformation of the receptor by breaking
the polar interaction. In contrast, in the model of the
active conformation of the TSHR TMD, Asn6747.49
makes a hydrogen bond with Asp4602.50 (Supplementary
Table 6, Fig. 3c). The TSHR mutant D460A reduces the
constitutive activity to 28% of the wild type (Table 7),
due to a destabilization of the active conformation of the
receptor by breaking the hydrogen bond.
In conclusion, to study activation of the GPHR TMDs,
we built comparative models of the inactive and fully
Table 4 TSH receptor-activating mutations reported in the literature
Mutation BW number Type Activity References
V421I 1.39 CAM cAMP 2.1-fold WT [73]
Y466A 2.56 CAM cAMP 2.8-fold WT [73]
I486N ECL1 CAM cAMP 4-fold WT [74]
T501A 3.32 CAM cAMP 3.4-fold WT [73]
L512R 3.43 CAM cAMP 3.2-fold WT [40]
A593G 5.50 CAM cAMP 2.13-fold WT [15]
L629F 6.40 CAM cAMP 2.2-fold WT [45]
F631I 6.42 CAM cAMP 3.7-fold WT [75]
T632A 6.43 CAM cAMP 9.7-fold WT [16]
D633A 6.44 CAM cAMP 13.6-fold WT [16]
D633E 6.44 CAM cAMP 3.3-fold WT [40]
C636R 6.47 CAM cAMP 7.7-fold WT [76]
C636S 6.47 CAM cAMP 5.5-fold WT [76]
M637C 6.48 CAM cAMP 2.4-fold WT [73]
M637W 6.48 CAM cAMP 4.8-fold WT [73]
P639G 6.50 CAM cAMP 4.9-fold WT [76]
P639A 6.50 CAM cAMP 4.8-fold WT [76]
P639S 6.50 CAM cAMP 4.8-fold WT [76]
S641A 6.52 CAM cAMP 3.1-fold WT [73]
Y643F 6.54 CAM cAMP 2.1-fold WT [73]
L645V 6.56 CAM cAMP 2.1-fold WT [73]
L665F 7.40 CAM cAMP 3-fold WT [14]
N674D 7.49 CAM cAMP 11.3-fold WT [16]
Mutations causing increase of constitutive activity less than twofold
of WT are not included
CAM constitutively active mutant, BW Ballesteros–Weinstein num-
bering, WT wild type
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Fig. 3 a Distances between
thyroid-stimulating hormone
receptor (TSHR) Leu6657.40 and
Val4211.39 and between
Val4241.42 and Leu4682.58 in the
inactive conformation (left
panel) and active conformation
(right panel) of the TSHR
transmembrane domain (TMD)
wild type. b Distances (dotted
lines) and interactions (solid
lines) between TSHR
Phe6657.40 and Val4211.39 and
between Val4241.42 and
Leu4682.58 in the inactive
conformation (left panel) and
active conformation (right
panel) of the TSHR TMD
L665F mutant. c Distances
(dotted lines) and interactions
(solid lines) of TSHR
Asn6747.49 with Asp460 and
Asp6336.44 in the inactive
conformation (left panel) and
active conformation (right
panel) and d between
Phe5945.51 and Phe6346.54 in the
inactive conformation (left
panel) and active conformation
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Table 5 FSH receptor-
inactivating/silencing mutations
reported in the literature
Mutation BW number Typea Activity References
I418S 2.60 Inactivating FSH-induced cAMP abolished [77]
A419T 2.61 Inactivating FSH-induced cAMP abolished [78]
P519T ECL2 Inactivating FSH-induced cAMP abolished [65]
R573C 6.36 Inactivating FSH-induced max. cAMP 30% WT [79]
A575V 6.38 Inactivating FSH-induced cAMP abolished [80]
P587H 6.50 Inactivating FSH-induced cAMP abolished [65]
L601V ECL3 Inactivating FSH-induced max. cAMP 20% WT [81]
BW Ballesteros–Weinstein numbering, WT wild type
a Mutation causing decrease of the receptor constitutive activity is defined as silencing. Mutation causing
decrease of hormone-induced cyclic AMP activity is defined as inactivating
Table 6 LH receptor
inactivating/silencing mutations
reported in the literature
Mutation BW number Typea Activity References
I374T 1.47 Inactivating – [82]
T392I ICL1 Inactivating – [82]
C543R 5.55 Inactivating LH-induced cAMP abolished [83]
A593P 6.59 Inactivating LH-induced cAMP abolished [84]
S616Y 7.46 Inactivating LH-induced EC50 20-fold WT [85]
I625K 7.55 Inactivating LH-induced EC50 20-fold WT [85]
BW Ballesteros–Weinstein numbering, WT wild type
a Mutation causing decrease of the receptor constitutive activity is defined as silencing. Mutation causing
decrease of hormone-induced cyclic AMP activity is defined as inactivating
Table 7 TSH receptor-
inactivating/silencing mutations
reported in the literature
Mutation BW number Typea Activity References
V424I 1.42 Silencing cAMP 0.3-fold WT [86]
D460A 2.50 Silencing cAMP 0.28-fold WT [16]
D460N 2.50 Silencing cAMP 0.18-fold WT [16]
L467V 2.57 Silencing cAMP 0.1-fold WT [86]
W488R ECL1 Inactivating TSH binding abolished [87]
V502A 3.33 Silencing cAMP 0.0-fold WT [86]
M527T ICL2 Inactivating TSH induced max. cAMP 30% WT [87]
Y582A 5.39 Silencing cAMP 0.2-fold WT [86]
Y582F 5.39 Silencing cAMP 0.4-fold WT [86]
A593P 5.50 Silencing cAMP 0.19-fold WT [15]
A593V 5.50 Silencing cAMP 0.33-fold WT [15]
F594I 5.51 Silencing cAMP 0.13-fold WT [15]
R625A 6.36 Silencing cAMP 0.11-fold WT [16]
F634I 6.45 Silencing cAMP 0.13-fold WT [15]
A638V 6.49 Inactivating TSH induced EC50 7.85-fold WT [15]
F642I 6.53 Inactivating TSH induced EC50 8.21-fold WT [15]
Y643A 6.54 Silencing cAMP 0.2-fold WT [86]
A644V 6.55 Inactivating TSH induced EC50 8.88-fold WT [15]
L665V 7.40 Silencing cAMP 0.3-fold WT [86]
Mutations causing decrease of constitutive activity above 0.5-fold of WT are not included
BW Ballesteros–Weinstein numbering, WT wild type
a Mutation causing decrease of the receptor constitutive activity is defined as silencing. Mutation causing
decrease of hormone-induced cyclic AMP activity is defined as inactivating
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active conformations of their TMDs based on three
GPCRs for which the crystal structures of both the
inactive and fully active conformations were available.
Most GPCR-conserved helix distortions are observed in
our models of both the active and inactive GPHR TMD
conformations. In addition, most GPCR TMD-conserved
motifs are observed in the amino acid sequences of the
GPHR TMDs. Some of these conserved helix distortions
and motifs have not been described previously for
GPHRs. Furthermore, GPCR transmembrane helix dis-
placements and rotations observed during receptor acti-
vation are also observed when comparing the inactive
and active conformations of the GPHR TMDs. In addi-
tion, our study also suggests GPHR-specific hydrophobic
interactions between residues at positions 3.30 and 4.58.
A detailed analysis of the active and inactive confor-
mations of GPHR TMD structures produced by com-
parative modelling has not been carried out before.
Furthermore, our TMD models were used to study the
effects of previously reported GPHR TMD mutations on
the molecular interactions and activity of the GPHRs
which had not been previously explained at the structural
level. We propose that the conformational modifications
of the transmembrane helices and rearrangements of
important interactions during activation of the GPHR
TMD are similar to those previously reported for GPCR
activation. During activation of GPHRs, an ionic lock is
broken and important hydrogen bonds and hydrophobic
interactions are rearranged. All these modifications open
the G-protein binding site at the cytoplasmic end of their
TMD structures.
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